Candidate Genes Identified in Systemic Sclerosis-Related Pulmonary Arterial Hypertension Were Associated with Immunity, Inflammation, and Cytokines

Zhixiao Xu,1 Jiaxing Ruan,1 Lingyun Pan,1 and Chengshui Chen1,2

1Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, Ouhai District, Wenzhou 325000, China
2The Interventional Pulmonary Key Laboratory of Zhejiang Province, Wenzhou 325000, Zhejiang, China

Correspondence should be addressed to Chengshui Chen; wzchencs@163.com

Received 18 October 2020; Revised 24 November 2020; Accepted 1 January 2021; Published 18 February 2021

Academic Editor: Francesco Santoro

Copyright © 2021 Zhixiao Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. Pulmonary complications of systemic sclerosis (SSc), including pulmonary arterial hypertension (PAH), are the leading causes of patient death. However, the precise molecular mechanisms of its etiology are unclear. This study’s objective was to identify the candidate genes involved in the progression of SSc-PAH and investigate the genes’ function. Methods. The gene expression profiles of GSE33463 were obtained from the Gene Expression Omnibus (GEO) database. A free-scale gene coexpression network was constructed using the weighted gene coexpression network analysis (WGCNA) to explore the association between gene sets and clinical features and identify candidate biomarkers. Then, gene ontology analysis was performed. A second dataset was used, GSE19617, to validate the hub genes. The verified hub genes’ potential function was further explored using gene set enrichment analysis (GSEA). Results. Through average link-level clustering, a total of seven modules were classified. A total of 938 hub genes were identified in the key module, and the key module’s function mainly enriched was related to chemokine activities. Subsequently, four candidate genes, BTG3, CCR2, RAB10, and TMEM60, were filtered. The expression levels of these four hub genes were consistent in the GSE19617 and GSE33463 datasets. We plotted the ROC curve of the hub genes (all AUC > 0.70). Furthermore, the results of the GSEA for hub genes were correlated with complement and inflammatory responses. Conclusions. The hub genes (BTG3, CCR2, RAB10, and TMEM60) performed well in distinguishing the SSc-PAH patients from controls, and some biological functions, related to immunity, inflammation, and cytokines, might pave the way for follow-up studies on the diagnosis and treatment of SSc-PAH.

1. Introduction

Systemic sclerosis (SSc), with a chronic progressive manner, is a rare systemic autoimmune disease [1]. A series of pathophysiological processes eventually lead to the deposition of excessive collagen and fibrosis in the skin and various organ systems, especially the lung [2]. Lung involvement in SSc consists of both interstitial lung diseases (ILD) and pulmonary hypertension (PAH), and it is worth noting that PAH is not uncommon in SSc [3] and might be more common in limited SSc [4]. At autopsy, PAH accounted for 8-12% of patient death [4]. It was estimated that PAH’s lifetime prevalence in SSc patients is 5-12% [5].

PAH is a destructive disease that causes distinctive remodeling of the intima, medial, and adventitia layers based on the small and medium pulmonary arteries, resulting in considerable narrowing of the pulmonary vascular lumen [5–7]. The final manifestation is an increase in mean pulmonary artery pressure at rest (mPAP ≥ 25 mmHg) [5, 6]. Lung involvement is a common cause of mortality in patients with SSc [8], of which ILD is the most common, followed by PAH [6]. Moreover, it was estimated that 30% of global PAH cases appeared to be connective tissue disease-related PAH, of which SSc-related PAH (SSc-PAH) accounted for the majority [9]. The risk of death from PAH based on ILD was five times higher than that of PAH alone [10]. The prognosis of
patients with SSc-PAH is abysmal. It has been reported that the 3-year mortality rate after PAH diagnosis was approximately 50% [5], while the latest 3-year survival rate was 75% [11]. In treatment, although the exercise capacity and quality of life have significantly improved in patients with idiopathic PAH (IPAH) due to vasodilators uses, there is no such trend in patients with SSc-PAH [2].

The weighted gene coexpression network analysis (WGCNA), which has been widely used to explore gene networks’ characteristics related to complex diseases [12], can be used to investigate the association between the genome and clinical features and identify candidate biomarkers. This study’s objective was to use WGCNA analysis to investigate the gene-network characteristics of peripheral blood associated with SSc-PAH and to identify the hub genes most relevant to SSc-PAH and to use gene set enrichment analysis (GSEA) of a single candidate gene to explore their potential function.

2. Materials and Methods

2.1. Gene Expression Data and Data Preprocessing. The dataset of RNA expression profiles of SSc-PAH was driven from the Gene Expression Omnibus (GEO) database (https://www.ncbi.nlm.nih.gov/GEO/). In this study, the microarray dataset GSE33463 [13] from whole peripheral blood in 42 SSc-PAH patients and 41 controls was obtained to build coexpression networks and identify hub genes related to SSc-PAH. Considering that the datasets used in this study were downloaded from the GEO database through publicly available methods, the imperative of informed consent was waived.

The R software (version 3.5.2; https://www.R-project.org/) and several packages were used for data mining and statistical analysis. Meaningfully, the “normalizeBetweenArrays” function of the “Limma” package [14] was used for normalization.

2.2. Screening of Differentially Expressed Genes. We screened the differentially expressed genes (DEGs) between SSc-PAH patients and normal controls in the expressing data by using the t-test in the “Limma” package in R. The cut-off criteria were defined as |log2 FC| >0.5, and adjusted P values <0.05.

2.3. Construction of Coexpression Network. Through the R package “WGCNA” [12], the DEGs’ coexpression network based on GSE33463 was constructed. In the coexpression network, based on the soft-thresholding power of 16 and the minimum number of genes in the module of 30, genes with high absolute correlations were clustered into the same module.

2.4. Gene Ontology and Pathway Enrichment Analysis. It would be more productive if gene ontology and pathway enrichment analysis were performed on a transcriptional module closely related to the trait. To further probe the function of the DEGs in the key module, the Gene Ontology (GO) analysis and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis were performed using the R package “clusterProfiler” [15], where GO analysis included molecular function (MF), biological processes (BP), and cellular component (CC). P < 0.05 was set as the cut-off standard.

2.5. Identification of Hub Genes in Clinically Significant Modules. Gene significance (GS) was evaluated by the mediated P value (GS = lqP) of each gene in a linear regression between gene expression and the clinical characteristics [16], while the genes’ connectivity was assessed by the absolute value of Pearson’s correlation.

In our study, genes with GS greater than 0.95 and ModuleMembership > 0.9 were considered to be the hub genes of the modules, reflecting a meaningful correlation with particular clinical features.

2.6. Genes Validation and Efficacy Evaluation. A second dataset GSE19617 [17], obtained from RNA extracted from peripheral blood mononuclear cells (PBMCs) in 17 patients with SSc-PAH and 12 healthy controls, was used to verify the hub genes. To evaluate the hub genes’ reliability to distinguish SSc-PAH patients from healthy controls, we plotted

| Table 1: The top 15 up-regulated genes and 15 down-regulated genes identified in the microarray dataset GSE33463. |
|---------------------------------------------------------------|
| **Gene symbol** | **logFC** | **P value** | **Adj. P value** |
|-----------------|-----------|-------------|-----------------|
| MOAP1           | 1.051413956 | 1.25E-21 | 2.01E-17         |
| MED10           | 0.757768783 | 1.77E-21 | 2.01E-17         |
| EIF1            | 0.949347975 | 9.48E-21 | 4.91E-17         |
| DNAJB1          | 1.235358669 | 9.76E-21 | 4.91E-17         |
| MYLIP           | 1.145187023 | 1.42E-20 | 5.36E-17         |
| DYNLL2          | 1.300670563 | 2.45E-20 | 7.69E-17         |
| SBDS            | 1.160211817 | 5.46E-20 | 1.18E-16         |
| CCDC59          | 0.943865194 | 5.61E-20 | 1.18E-16         |
| PTPNC1          | 0.729721186 | 7.93E-20 | 1.53E-16         |
| LOC652773       | 0.833258361 | 2.19E-19 | 3.07E-16         |
| LOC388275       | 0.765982809 | 3.01E-19 | 3.79E-16         |
| MGAT4A          | 1.340399036 | 6.79E-19 | 7.77E-16         |
| TOMM20          | 0.627280790 | 7.46E-19 | 8.16E-16         |
| TIGA1           | 0.820889344 | 8.78E-19 | 9.20E-16         |
| IRF2BP2         | 0.974930681 | 1.42E-18 | 1.38E-15         |
| TMEM60          | -1.131294044 | 2.40E-20 | 2.01E-17         |
| EXOSC3          | -0.835661131 | 1.49E-20 | 5.36E-17         |
| ASH2L           | -0.588897110 | 3.02E-20 | 8.44E-17         |
| GIMAP4          | -1.639178038 | 4.24E-20 | 1.07E-16         |
| FPR2            | -1.495763022 | 1.10E-19 | 1.85E-16         |
| TNFAIP8L2       | -9.904959224 | 1.51E-19 | 2.37E-16         |
| SCO1            | -0.615800262 | 1.67E-19 | 2.48E-16         |
| CRIP1           | -0.737821571 | 2.59E-19 | 3.43E-16         |
| NFE2            | -1.595721981 | 5.07E-19 | 6.07E-16         |
| RNF149          | -1.090753168 | 9.18E-19 | 9.24E-16         |
| COPB2           | -0.823346942 | 1.97E-18 | 1.77E-15         |
| APEX2           | -0.546065608 | 2.34E-18 | 2.03E-15         |
| SAMD9L          | -1.095909062 | 2.65E-18 | 2.17E-15         |
| LFNG            | -1.479067449 | 2.84E-18 | 2.23E-15         |
Sample clustering to detect outliers

(a)

Scale independence

Mean connectivity

(b)

(c)

Figure 1: Continued.
receiver operating characteristic (ROC) curves and calculated the area under curves (AUCs).

2.7. Gene Set Enrichment Analysis. GSEA of a single candidate gene was conducted using the R package “clusterProfiler” to explore the potential function of the proper candidate genes in SSc-PAH. We use the h.all.v7.0.entrez.gmt in the Molecular Signatures Database as the reference gene set. We chose the adjusted $P$ value < 0.05 as the cut-off criterion.

3. Results

3.1. Differentially Expressed Genes between SSc-PAH and Normal Controls. A total of 938 DEGs were identified in the gene expression microarray study of 42 SSc-PAH patients and 41 controls, and the top 15 up-regulated genes and 15 down-regulated genes are shown in Table 1. These DEGs were selected for subsequent analysis.

3.2. Coexpression Network Construction of the SSc-PAH and Normal Conditions. After using the average method of the “hclust” function to evaluate the expression matrix, the gene chip (GSM827775) with a cluster height exceeding 40 exhibited deviation and was excluded from further analysis (Figure 1(a)). The soft-thresholding parameter was selected as 16 (scale-free $R^2 = 0.9$) to ensure a scale-free network when 0.9 was used as the correlation coefficient threshold (Figures 1(b) and 1(c)). Seven coexpression modules were constructed using WGCNA analysis (Figure 2(a)), which contained the most genes in was the turquoise module. And these coexpression modules were independent of other modules (Figure 2(b)).

3.3. Identification of Clinically Significant Modules and Hub Genes. Since the turquoise module had the highest correlation with SSc-PAH and a high correlation with clinical characteristics among all modules, the turquoise module was selected for further analysis (Figures 2(c) and 2(d)). Based on the cut-off criteria ($|\text{MM}| > 0.95$ and $|\text{GS}| > 0.90$), 27 genes with high connectivity in the clinically important module were identified as hub genes. Notably, some genes in the turquoise module, including “BTG3,” “C12orf41,” “CCR2,” “COPB2,” “DYNLL2,” “ETNK1,” “GIMAP4,” “GIMAP8,” “HSPA1A,” “LFNG,” “LOC653171,” “LOC731878,” “RAB10,” “TMEM60,” “TNFAIP3,” and “TNFAIP8L2,” had high gene significance for SSc-PAH (Figures 2(e) and 2(f)). This indicated

![Figure 1](image-url)
Gene dendrogram and module colors

(a)

Network heat map plot, selected genes

(b)

Figure 2: Continued.
Module–trait relationships

(c)

Gene significance across modules, $P$ value = $1.3 \times 10^{-90}$

(d)

Module membership vs. gene significance
$cor = 0.7$, $p = 1.3 \times 10^{-45}$

(e)

Figure 2: Continued.
that these genes mentioned above were also closely correlated with each other (Figure 2(f)).

3.4. Functional Annotation of the Key Module. GO analysis showed that the genes in the turquoise module were mainly enriched in C-C chemokine receptor activity, C-C chemokine binding, G protein-coupled chemoattractant receptor activity, and chemokine receptor activity. The relationship between these genes and GO terms suggested that many genes were linked to immune response and inflammation (Table 2). No significant results were observed for KEGG enrichment.

![Unsigned correlation](f)

**Table 2: Gene ontology enrichment analysis of turquoise module genes.**

| Term | Description | Count | P adjust |
|------|-------------|-------|----------|
| GO:0016493 | C-C chemokine receptor activity | 4 | 0.029688 |
| GO:0019957 | C-C chemokine binding | 4 | 0.029688 |
| GO:0001637 | G protein-coupled chemoattractant receptor activity | 4 | 0.029688 |
| GO:0004950 | Chemokine receptor activity | 4 | 0.029688 |
| GO:0019956 | Chemokine binding | 4 | 0.045889 |
| GO:0004519 | Endonuclease activity | 7 | 0.045889 |
| GO:0004518 | Nuclease activity | 9 | 0.045889 |
| GO:0005159 | Insulin-like growth factor receptor binding | 3 | 0.045889 |
| GO:0061630 | Ubiquitin protein ligase activity | 9 | 0.045889 |
| GO:0004521 | Endoribonuclease activity | 5 | 0.045889 |
| GO:0061659 | Ubiquitin-like protein ligase activity | 9 | 0.048451 |
Figure 3: Continued.

(a) $t(70.015) = -8.791, \ p < 0.001, \ g = 0.991, \ 95\% \ CI \ [-2.444, -1.398], \ n = 83$

(b) $t(77.913) = 10.028, \ p < 0.001, \ g = 0.991, \ 95\% \ CI \ [1.639, 2.733], \ n = 83$

(c) $t(57.133) = 9.901, \ p < 0.001, \ g = 0.991, \ 95\% \ CI \ [1.625, 2.716], \ n = 83$
Figure 3: Continued.
Figure 3: Continued.
3.5. Validation and Efficacy Evaluation of Hub Genes.

In dataset GSE33463, the expression of four genes, B cell translocation gene 3 (BTG3), C-C motif chemokine receptor 2 (CCR2), member RAS oncogene family (RAB10), and transmembrane protein 60 (TMEM60), was notably increased or decreased in the PBMCs of SSc-PAH patients compared with the controls (Figures 3(a)–3(d)). In addition, in the second dataset GSE19617, the expression of BTG3, CCR2, RAB10, and TMEM60 (all $P < 0.05$) was also considerably up-regulated or down-regulated in the SSc-PAH patients (Figures 3(e)–3(h)). Furthermore, to distinguish SSc-PAH from the controls, we used the ROC curves to calculate the AUCs. The AUC of each gene in datasets GSE19617 and GSE33463 was greater than 0.7 (Figures 3(i) and 3(j)).

3.6. Gene Set Enrichment Analysis.

The complete list of gene sets enriched in samples with a high expression of BTG3, CCR2, RAB10, or TMEM60 was found through GSEA (Figures 4(a)–4(d)). The gene sets related to immunity and inflammation among the complete list were used for further analysis. “Complement” was enriched in samples in which CCR2 and RAB10 were highly expressed (Figures 4(f) and 4(g)). Similarly, the samples with a high expression of BTG3 and TMEM60 were enriched in “inflammatory response” (Figures 4(e) and 4(h)). Moreover, “tumor necrosis factor-α (TNF-α) signaling via nuclear factor-kappa B (NF-κB)” and “mammalian target of rapamycin complex 1 (mTORC1) signaling” were enriched in the samples with a high expression of any one of BTG3, CCR2, RAB10, or TMEM60 (Figures 4(e)–4(h)).

4. Discussion

Recent studies have provided new clues into the critical signaling pathways of PAH. These signaling pathways include inflammation, immune activation, endothelial dysfunction, and growth factors [5]. In this study, we built a coexpression network of SSc-PAH-related genes through WGCNA analysis. The association of modules and traits was constructed and visualized as a heat map to find the modules most relevant to PAH. The turquoise module was the most important in SSc-PAH, and hub genes in this module associated with SSc-PAH pathogenesis were discovered. The study’s outcome indicated that candidate genes identified in SSc-PAH were associated with immunity, inflammation, and cytokines.

Some genes deemed as hub genes could play significant roles in the pathogenesis of SSc-PAH. Pulmonary vascular cells in PAH have similar phenotypic characteristics to tumor cells in hyperproliferation and antiapoptosis [18]. By down-regulating BTG3, miR-142-5p promotes the proliferation of vascular smooth muscle cells [19]. Although some findings indicated that CCR2 could not directly promote PAH development, it might play a previously unrecognized role in developing and remodeling pulmonary blood vessels [20]. Guanosine-5′-triphosphatase IMAP family member 4 (GIMAP4) is a locus that strongly affects susceptibility to vasculitis [21]. Considering the anti-inflammatory properties of heat shock protein A1A (HSPA1A) [22], low levels of intracellular and circulating HSPA1A would promote the proinflammatory state and increase the vulnerability of the arterial wall to the destructive effects of vascular risk factors connected with endothelial dysfunction [23].
**Figure 4: Continued.**

(a) and (b) show pathway activation and suppression for different gene ratios. The pathways include:

- Hallmark Cholesterol Homoeostasis
- Hallmark Interferon Gamma Response
- Hallmark TNFα Signaling Via NFκB
- Hallmark Heme Metabolism
- Hallmark Protein Secretion
- Hallmark P53 Pathway
- Hallmark Unfolded Protein Response
- Hallmark Inflammatory Response
- Hallmark Apoptosis
- Hallmark Oxidative Phosphorylation
- Hallmark UV Response Up
- Hallmark Hypoxia

The graphs depict changes in gene expression ratios with adjusted *p*-values for each pathway.
Figure 4: Continued.
Figure 4: Continued.
Figure 4: (a–d) Gene set enrichment analysis (GSEA). The full list of gene sets enriched in samples with a high expression of BTG3 (a), CCR2 (b), RAB10 (c), and TMEM60 (d). (e–g) Gene sets related to immunity and inflammation. Gene sets related to immunity and inflammation enriched in samples with a high expression of BTG3 (e), CCR2 (f), RAB10 (h), and TMEM60 (g). BTG3: B cell translocation gene 3; CCR2: C-C motif chemokine receptor 2; RAB10: member RAS oncogene family; TMEM60: transmembrane protein 60.
studies have shown that decreased expression of tumor necrosis factor-α-induced protein 8 (TNFAIP8), leading to reduced levels of vascular endothelial growth factor receptor 2 (VEGFR-2) [24]. The antiapoptotic effects could partially mediate the therapeutic effects of endothelial progenitor cell transplantation in PAH. However, the antiapoptotic effect of the conditioned medium of endothelial progenitor cells was attenuated by blocking VEGFR-2 [25]. Similarly, Pendergrass et al. found inflammatory mediators such as TNF-α and markers of vascular injury such as VEGF in SSc-PAH subjects [17]. Grigoriev et al. confirmed by real-time PCR that VEGF was significantly up-regulated in mild cases compared with severe PAH and healthy controls [26]. Polymorphisms within the tumor necrosis factor-α-induced protein 3 (TNFAIP3) genomic locus have been linked to multiple inflammatory and autoimmune diseases [27]. These genes have not been further elucidated in SSc-PAH. Hemmes et al. successfully distinguished the vasodilator-responsive and nonresponsive forms of PAH, but there are few relevant studies on SSc-PAH [28].

Among hub genes, in dataset GSE33463, the expression of BTG3, CCR2, RAB10, and TMEM60 was significantly increased or decreased in the SSc-PAH patients compared with healthy controls. Simultaneously, we confirmed the above four hub genes’ expression levels in GSE19617, and their expression in PBMCs was also significantly up- or down-regulated. In the future, more experiments are needed to illuminate their expression and related functions in different ethnic groups.

Because the genes within a module were closely related in function, we performed GO analysis to investigate genes’ biological functions in the turquoise module. The results indicated that the genes were mainly enriched in C-C chemokine receptor activity, C-C chemokine binding, G protein-coupled chemotactant receptor activity, and chemokine receptor activity. There was no doubt that SSc manifested itself as an immune system disorder and endothelial dysfunction [29]. Various studies have shown that the immune processes originating in the lungs seemed to promote PAH development and were likely to leave evident fingerprints in the systemic circulation [30]. Hemmes et al. found extensive differences in RNA expression patterns using microarray analysis, as well as cell-cell adhesion factors [28].

Furthermore, our study revealed that “inflammatory response” and “complement” were involved in the pathogenesis of SSc-PAH. Immunoglobulin-driven complement activation could regulate proinflammatory remodeling in PAH [31]. Besides, “TNF-α signaling via NF-κB” and “mTORC1 signaling” were also enriched. TNF-α, one of the inflammatory mediators, was found in SSc-PAH subjects [17]. Baicalin inhibited pulmonary artery remodeling in rats at least in part through NF-κB pathways [32]. In mice, loss of the D prostaglandin receptor subtype one aggravated vascular remodeling in PAH via mTORC1 signaling [33]. Aldosterone could upregulate the mammalian target of the rapamycin complex one subunit raptor, inducing abnormal survival patterns of pulmonary artery smooth muscle cells to promote PAH [34].

Our study also had limitations. First, due to GEO’s incomplete data, some patients’ characteristics were unknown, including autoantibodies. Second, many biomarkers related to SSc-PAH remain puzzling, and further bioinformatics analysis and experimental confirmation are needed to detail the biological functions of these genes in SSc-PAH. Third, we used data from only two different studies in our WGCNA analysis and validation of hub genes. Microarray samples need to be extracted from patients with varying degrees of PAH, and more samples are needed.

5. Conclusions
In summary, we identified the hub genes in the key gene coexpression modules, and the four genes (BTG3, CCR2, RAB10, and TMEM60) play an essential role in the diagnosis of SSc-PAH patients. Some functional biological pathways linking immunity, inflammation, and cytokines play a critical role in the pathogenesis of SSc-PAH. These results provide new insights into SSc-PAH diagnosis and treatment, although the precise mechanisms still require further exploration.

Data Availability
The datasets analyzed during this study were publicly available databases, such as the Gene Expression Omnibus (GEO) dataset.

Conflicts of Interest
The authors declare that they have no competing interests.

Authors’ Contributions
Chengshui Chen contributed to the design of this study and manuscript revision. Zhixiao Xu contributed to the data collection and analysis and manuscript drafting. Jiaxing Ruan contributed to the data analysis and manuscript revision. Lingyun Pan contributed to the data curation and manuscript revision.

Acknowledgments
This work was financially supported by the National Key Research and Development Program of China (2016YFC1304000), The Interventional Pulmonary Key Laboratory of Zhejiang Province (2019E10014), and The Interventional Pulmonology Key Laboratory of Wenzhou City.

References
[1] V. Cottin and K. K. Brown, “Interstitial lung disease associated with systemic sclerosis (SSc-ILD),” Respiratory Research, vol. 20, no. 1, p. 13, 2019.
[2] R. G. Argula, C. Ward, and C. Feghali-Bostwick, “Therapeutic challenges and advances in the management of systemic sclerosis-related pulmonary arterial hypertension (SSc-PAH),” Therapeutics and Clinical Risk Management, vol. 15, pp. 1427–1442, 2019.
A. Fischer, T. M. Bull, and V. D. Steen, “Practical approach to screening for scleroderma-associated pulmonary arterial hypertension,” *Arthritis Care & Research*, vol. 64, no. 3, pp. 303–310, 2012.

S. C. Mathai and S. K. Danoff, “Management of interstitial lung disease associated with connective tissue disease,” *BMJ*, vol. 352, article h6819, 2016.

B. Odler, V. Foris, A. Gungl et al., “Biomarkers for pulmonary vascular remodeling in systemic sclerosis: a pathophysiological approach,” *Frontiers in Physiology*, vol. 9, p. 587, 2018.

S. R. Schoenfeld and F. V. Castelino, “Evaluation and management approaches for scleroderma lung disease,” *Therapeutic Advances in Respiratory Disease*, vol. 11, no. 8, pp. 327–340, 2017.

R. M. Tudor, E. Stacher, J. Robinson, R. Kumar, and B. B. Graham, “Pathology of pulmonary hypertension,” *Clinics in Chest Medicine*, vol. 34, no. 4, pp. 639–650, 2013.

V. D. Steen and T. A. Medsger, “Changes in causes of death in systemic sclerosis, 1972-2002,” *Annals of the Rheumatic Diseases*, vol. 66, no. 7, pp. 940–944, 2007.

J. G. Coghlan and C. Handler, “Connective tissue associated pulmonary arterial hypertension,” *Lupus*, vol. 15, no. 3, pp. 138–142, 2006.

S. C. Mathai, L. K. Hummers, H. C. Champion et al., “Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease,” *Arthritis & Rheumatism*, vol. 60, no. 2, pp. 569–577, 2009.

K. D. Kolstad, S. Li, V. Steen et al., “Long-term outcomes in systemic sclerosis-associated pulmonary arterial hypertension from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry (PHAROS),” *Chest*, vol. 154, no. 4, pp. 862–871, 2018.

P. Langfelder and S. Horvath, “WGCNA: an R package for weighted correlation network analysis,” *BMC Bioinformatics*, vol. 9, p. 559, 2008.

C. Cheadle, A. E. Berger, S. C. Mathai et al., “Erythroid-specific transcriptional changes in PBMCs from pulmonary hypertension patients,” *PLoS One*, vol. 7, no. 4, article e34951, 2012.

M. E. Ritchie, B. Phipson, Y. H. Di Wu, C. W. Law, W. Shi, and G. K. Smyth, “Limma powers differential expression analyses for RNA-sequencing and microarray studies,” *Nucleic Acids Research*, vol. 43, no. 7, p. e47, 2015.

G. Yu, L.-G. Wang, Y. Han, and Q.-Y. He, “clusterProfiler: an R package for comparing biological themes among gene clusters,” *OMICS: A Journal of Integrative Biology*, vol. 16, no. 5, pp. 284–287, 2012.

P. Langfelder and S. Horvath, “Eigengene networks for studying the relationships between co-expression modules,” *BMC Systems Biology*, vol. 1, p. 54, 2007.

S. A. Pendergrass, E. Hayes, G. Farina et al., “Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury,” *PLoS One*, vol. 5, no. 8, article e12106, 2010.

S. Sakao and K. Tatsumi, “Vascular remodeling in pulmonary arterial hypertension: multiple cancer-like pathways and possible treatment modalities,” *International Journal of Cardiology*, vol. 147, no. 1, pp. 4–12, 2011.

H. J. Kee, S. Park, J.-S. Kwon et al., “B cell translocation gene, a direct target of miR-142-5p, inhibits vascular smooth muscle cell proliferation by down-regulating cell cycle progression,” *FEBS Letters*, vol. 587, no. 15, pp. 2385–2392, 2013.

Y.-R. A. Yu, L. Mao, C. A. Piantadosi, and M. D. Gunn, “CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension,” *American Journal of Respiratory Cell and Molecular Biology*, vol. 48, no. 5, pp. 647–654, 2013.

F. D. Carmona, J. Martin, and M. A. González-Gay, “Genetics of vasculitis,” *Current Opinion in Rheumatology*, vol. 27, no. 1, pp. 10–17, 2015.

M. Shvetsov, G. Huile, and G. Multhoff, “Membrane heat shock protein 70: a theranostic target for cancer therapy,” *Philosophical Transactions of the Royal Society B: Biological Sciences*, vol. 373, no. 1738, 2018.

E. Dulin, P. García-Barreno, and M. C. Guisasola, “Genetic variations of HSPA1A, the heat shock protein levels, and risk of atherosclerosis,” *Cell Stress Chaperones*, vol. 17, no. 4, pp. 507–516, 2012.

C. Zhang, D. Chakravarty, I. Sakabe et al., “Role of SCC-S2 in experimental metastasis and modulation of VEGFR-2, MMP-1, and MMP-9 expression,” *Molecular Therapy*, vol. 13, no. 5, pp. 947–955, 2006.

L. Xia, G.-S. Fu, J.-X. Yang, F.-R. Zhang, and X.-X. Wang, “Endothelial progenitor cells may inhibit apoptosis of pulmonary microvascular endothelial cells: new insights into cell therapy for pulmonary arterial hypertension,” *Cytotherapy*, vol. 11, no. 4, pp. 492–502, 2009.

D. N. Grigoriev, S. C. Mathai, M. R. Fisher et al., “Identification of candidate genes in scleroderma-related pulmonary arterial hypertension,” *Translational Research*, vol. 151, no. 4, pp. 197–207, 2008.

L. Vereecke, R. Beyaert, and G. van Loo, “Genetic relationships between A20/TNFAIP3, chronic inflammation and autoimmune disease,” *Biochemical Society Transactions*, vol. 39, no. 4, pp. 1086–1091, 2011.

A. R. Hemmes, A. W. Trammell, S. L. Archer et al., “Peripheral blood signature of vasodilator-responsive pulmonary arterial hypertension,” *Circulation*, vol. 131, no. 4, pp. 401–409, 2015.

C. E. Simpson, R. L. Damico, L. Hummers et al., “Serum uric acid as a marker of disease risk, severity, and survival in systemic sclerosis-related pulmonary arterial hypertension,” *Pulmonary Circulation*, vol. 9, no. 3, 2019.

A.-M. Hoffmann-Vold, R. Hesselstrand, H. Frethis et al., “CCL21 as a potential serum biomarker for pulmonary arterial hypertension in systemic sclerosis,” *Arthritis & Rheumatology*, vol. 70, no. 10, pp. 1644–1653, 2018.

M. G. Frid, B. A. McKeon, J. M. Thurman et al., “Immunoglobulin-driven complement activation regulates proinflammatory remodeling in pulmonary hypertension,” *American Journal of Respiratory and Critical Care Medicine*, vol. 201, no. 2, pp. 224–239, 2020.

R. Shi, Z. Wei, D. Zhu et al., “Baicalein attenuates monocrotaline-induced pulmonary arterial hypertension by inhibiting vascular remodeling in rats,” *Pulmonary Pharmacology & Therapeutics*, vol. 48, pp. 124–135, 2018.
[33] Y. He, C. Zuo, D. Jia et al., “Loss of DP1 aggravates vascular remodeling in pulmonary arterial hypertension via mTORC1 signaling,” *American Journal of Respiratory and Critical Care Medicine*, vol. 201, no. 10, pp. 1263–1276, 2020.

[34] R. Aghamohammadzadeh, Y.-. Y. Zhang, T. E. Stephens et al., “Up-regulation of the mammalian target of rapamycin complex 1 subunit raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension,” *The FASEB Journal*, vol. 30, no. 7, pp. 2511–2527, 2016.